Amedeo Smart

Free Medical Literature Service

 

Amedeo

Tuberculosis
  Free Subscription

Articles published in
J Infect Dis
    September 2026
  1. ALKHAFAJI S, Yang E, Lee K, Chang VK, et al
    Ethambutol Population Pharmacokinetics and Pharmacodynamics From a Phase 3 Confirmatory Trial for the Treatment of Tuberculosis.
    J Infect Dis. 2026 Sep 30:jiag431. doi: 10.1093.
    >> Share

  2. DANCHIK C, Chinmayi GVA, Lee GY, Maruthai K, et al
    The Phosphate-Specific Transport System Gene pstA1 Contributes to Rifampin Tolerance in Mycobacterium tuberculosis.
    J Infect Dis. 2026 Sep 23:jiag483. doi: 10.1093.
    >> Share

  3. CHUNG TK, Yang E, Shin M, Solans BP, et al
    Pharmacokinetics and Dose Optimization of Ethambutol in Children on First-Line Antituberculosis Therapy: An Individual Patient Data Meta-Analysis.
    J Infect Dis. 2026;234:e613-e622.
    >> Share

  4. LOCKS LM, Kaipilyawar V, Jain K, VanValkenburg A, et al
    Attenuated Mycobacterium tuberculosis-specific Th1 cytokine responses in household contacts with undernutrition and their partial reconstitution during six months of nutritional support.
    J Infect Dis. 2026 Sep 8:jiag464. doi: 10.1093.
    >> Share

  5. NOGUEIRA BMF, Vinhaes CL, Rangel FA, Fukutani ER, et al
    Hyperinflammatory Profiles and Early Mortality in HIV-Associated Tuberculosis: A Prospective Cohort Study in Brazil.
    J Infect Dis. 2026 Sep 7:jiag458. doi: 10.1093.
    >> Share

    August 2026
  6. WATTIAU P, Omar SV, Joseph L, Demoitie MA, et al
    Genetic characterization of M. tuberculosis isolates from participants in a Phase 2b randomized trial evaluating the M72/AS01E tuberculosis candidate vaccine.
    J Infect Dis. 2026 Aug 28:jiag428. doi: 10.1093.
    >> Share

  7. MARTINEZ-LOPEZ YE, Black BW, Lee J, Buta BJ, et al
    Frailty as a framework to understand tuberculosis severity, recovery and sequelae.
    J Infect Dis. 2026 Aug 14:jiag415. doi: 10.1093.
    >> Share

  8. NORTIER E, Boczar MM, Hughes JA, van der Westhuizen JN, et al
    Pharmacokinetics and Safety of a Novel Clofazimine Formulation and Dosing Strategy in Children With Rifampicin-resistant Tuberculosis.
    J Infect Dis. 2026 Aug 13:jiag381. doi: 10.1093.
    >> Share

  9. TSAI CY, Xie M, Cristaldo M, Peluso GR, et al
    BCG vaccination with adjunctive APRIL immunotherapy reduces tuberculosis relapse in mice.
    J Infect Dis. 2026 Aug 12:jiag416. doi: 10.1093.
    >> Share

    July 2026
  10. ALONSO-RODRIGUEZ N, Edlund IH, Aass HCD, Sopegno C, et al
    CD4+ T cell markers associated with Treatment Outcomes in Tuberculosis: A Sub-analysis of a Phase IIB Trial of Acetylsalicylic acid and Ibuprofen as Adjunctive Therapy.
    J Infect Dis. 2026 Jul 29:jiag380. doi: 10.1093.
    >> Share

    June 2026
  11. YENGKHOM D, Weinberg A
    Tuberculosis in pregnancy: Challenges of immune protection.
    J Infect Dis. 2026 Jun 29:jiag345. doi: 10.1093.
    >> Share

  12. COLEMAN M, Manyara A, Calderwood CJ, de Wilton A, et al
    People with prior tuberculosis have accelerated frailty and differential survival into older age: a cross-sectional analysis in Southern Africa.
    J Infect Dis. 2026 Jun 12:jiag299. doi: 10.1093.
    >> Share

    May 2026
  13. HUGHES JA, Brooks KM, Fairlie L, Best BM, et al
    Letter Reply to "Mind the Postpartum Trough: Closing the Clofazimine Exposure Gap After Delivery in Rifampicin-Resistant Tuberculosis".
    J Infect Dis. 2026 May 18:jiag231. doi: 10.1093.
    >> Share

  14. PITCHENIK AE
    A missed early signal of the HIV-tuberculosis syndemic in a 1982 MMWR report.
    J Infect Dis. 2026 May 8:jiag261. doi: 10.1093.
    >> Share

  15. PRODANUK M, Boillat-Blanco N, D'Acremont V, Fung A, et al
    Host plasma protein biomarkers for tuberculosis disease screening in febrile adults in Tanzania.
    J Infect Dis. 2026 May 6:jiag238. doi: 10.1093.
    >> Share

    April 2026
  16. ZHANG H, Medina-Jaudes N, Forcada-Nadal A, Harrison EM, et al
    In Host Mutational Adaptation of Mycobacterium Tuberculosis Complex Strains During Tuberculosis Infection.
    J Infect Dis. 2026 Apr 28:jiag209. doi: 10.1093.
    >> Share

  17. CHEN R, Li B
    Mind the Postpartum Trough: Closing the Clofazimine Exposure Gap After Delivery in Rifampicin-Resistant Tuberculosis.
    J Infect Dis. 2026 Apr 23:jiag230. doi: 10.1093.
    >> Share

  18. STEIN CM, Benchek P, Mantshoyane L, Ciesielski T, et al
    Human genetic variation associates with infection by derived Ugandan M. tuberculosis lineage.
    J Infect Dis. 2026 Apr 18:jiag218. doi: 10.1093.
    >> Share

  19. GHANEM M, Srivastava R, Ektefaie Y, Hoppes D, et al
    Tuberculosis Disease Severity Assessment Using Clinical Variables and Radiology Enabled by Artificial Intelligence.
    J Infect Dis. 2026 Apr 16:jiag149. doi: 10.1093.
    >> Share

    March 2026
  20. ALFFENAAR JC, Stocker SL, Schon T
    Does one dose fit all in tuberculosis meningitis treatment?
    J Infect Dis. 2026 Mar 30:jiag195. doi: 10.1093.
    >> Share

    February 2026
  21. CHEN X, Ruiz-Gonzalez CE, Masias-Leon Y, Singh M, et al
    Addition of Clofazimine Enhances the Activity of Standard Treatment Regimen in a Mouse Model of Tuberculous Meningitis.
    J Infect Dis. 2026 Feb 23:jiag123. doi: 10.1093.
    >> Share

  22. JUNG E, Bampi JVB, Moura da Silva A, Liu YE, et al
    Longitudinal symptom transitions predict incident tuberculosis risk in serial active case finding.
    J Infect Dis. 2026 Feb 21:jiag119. doi: 10.1093.
    >> Share

  23. MULENGA H, Mendelsohn SC, Fiore-Gartland A, Penn-Nicholson A, et al
    Risk factors for immunological sensitization to Mycobacterium tuberculosis and progression to incident TB disease among HIV-uninfected adults in a high burden setting.
    J Infect Dis. 2026 Feb 18:jiag100. doi: 10.1093.
    >> Share

  24. NIETO RAMIREZ LM, Shelton K, Belisle JT, Diaz G, et al
    Optimized Mass Spectrometry to Uncover M. tuberculosis Biomarkers in Extracellular Vesicles from Asymptomatic Tuberculosis Patients.
    J Infect Dis. 2026 Feb 10:jiag086. doi: 10.1093.
    >> Share

  25. CHEN X, Ruiz-Gonzalez CE, Masias-Leon Y, Singh M, et al
    Beyond Rifampin: Evaluating Rifapentine and Rifabutin as Alternative Treatments for TB Meningitis.
    J Infect Dis. 2026 Feb 10:jiag087. doi: 10.1093.
    >> Share

    January 2026
  26. RYCKMAN TS, Shrestha S, Fojo AT, Kasaie P, et al
    Modeling the impact of case finding for tuberculosis: The role of infection dynamics.
    J Infect Dis. 2026 Jan 30:jiag050. doi: 10.1093.
    >> Share

  27. GAFAR F, Svensson EM, Yunivita V, Fregonese F, et al
    Population pharmacokinetic modeling of standard- and high-dose rifampicin for tuberculosis preventive therapy in the 2R2 randomized controlled trial.
    J Infect Dis. 2026 Jan 27:jiag052. doi: 10.1093.
    >> Share

  28. LACOURSE SM, Escudero JN, Whatney WE, Krish KN, et al
    Mtb-specific CFP-10/ESAT-6 CD4 and CD8 T cell non-IFN-gamma+ responses are common in young Kenyan children despite low reported TB exposure.
    J Infect Dis. 2026 Jan 21:jiag039. doi: 10.1093.
    >> Share

  29. JI J, Jiang X, Liao X, Du F, et al
    A monovalent SMAC mimetic as a potential host-directed therapy for tuberculosis.
    J Infect Dis. 2026 Jan 20:jiag031. doi: 10.1093.
    >> Share

  30. WILT AL, Meya DB, Cresswell FV, Wele A, et al
    CSF Hypo-Inflammation Drives Mortality in HIV-Associated Tuberculous Meningitis.
    J Infect Dis. 2026 Jan 12:jiag032. doi: 10.1093.
    >> Share

  31. YATES TA, Barr DA
    Re: Estimating the Early Transmission Inhibition of New Treatment Regimens for Drug-Resistant Tuberculosis.
    J Infect Dis. 2026 Jan 9:jiaf655. doi: 10.1093.
    >> Share

    December 2025
  32. AGUIRRE M, Ayala D, Garcia JI, Martinez-Lopez YE, et al
    Accuracy of the phenotypic 1G test to detect Mycobacterium tuberculosis and drug resistance from sputa in the US-Mexico border.
    J Infect Dis. 2025 Dec 23:jiaf638. doi: 10.1093.
    >> Share

  33. ERNST JD
    Clinical Commentary on: Targeting Tryptophan Metabolism for Tuberculosis Biomarkers and Host Directed Therapy.
    J Infect Dis. 2025 Dec 11:jiaf624. doi: 10.1093.
    >> Share

    November 2025
  34. LEPKA DE LIMA E, Aliberti MJR
    Childhood tuberculosis and risk of frailty in later life: evidence from a nationally representative study in Brazil.
    J Infect Dis. 2025 Nov 5:jiaf563. doi: 10.1093.
    >> Share

    October 2025
  35. HUGHES JA, McMorrow F, Brooks KM, Pinilla M, et al
    Pharmacokinetics and Safety of Clofazimine in Women With Rifampicin-resistant Tuberculosis During Pregnancy and the Postpartum Period: Results From IMPAACT P1026s.
    J Infect Dis. 2025 Oct 30:jiaf504. doi: 10.1093.
    >> Share

  36. MALATESTA S, Carney T, Niemand Wolhuter N, Overbeck V, et al
    Tuberculosis Disease Prevalence Among People Who Smoke Illicit Drugs: A Respondent- Driven Sampling Study in the Western Cape, South Africa.
    J Infect Dis. 2025 Oct 8:jiaf481. doi: 10.1093.
    >> Share

  37. WARD M, Zumbo P, Joseph Y, Apollon A, et al
    Increased plasmacytoid dendritic cells and inflammation persist in people with HIV years after tuberculosis.
    J Infect Dis. 2025 Oct 7:jiaf499. doi: 10.1093.
    >> Share

  38. MOONAN PK, Mathew SO, Simecka JW, Weis SE, et al
    Restoring TB-specific immunity in early HIV infection-the dual promise of early antiretroviral and TB preventive treatment.
    J Infect Dis. 2025 Oct 6:jiaf518. doi: 10.1093.
    >> Share

  39. COLLINS JM, Tukvadze N, Kempker RR
    Targeting Tryptophan Metabolism for Tuberculosis Biomarkers and Host Directed Therapy.
    J Infect Dis. 2025 Oct 1:jiaf510. doi: 10.1093.
    >> Share

  40. HIRANBURANA N, Sophonphan J, Kerr SJ, Ubolyam S, et al
    NAT2 polymorphisms and Antituberculosis-Induced Hepatotoxicity in Thai People Living with HIV: Insights from a Pharmacogenetic-Pharmacokinetic Cohort Study.
    J Infect Dis. 2025 Oct 1:jiaf511. doi: 10.1093.
    >> Share

    September 2025
  41. OKOYE M, Okoi C, Espy N, Mba N, et al
    Leveraging PEPFAR- and Global Fund-Supported Laboratory Network for Integrated Disease Testing: Lessons From Integrated HIV, Tuberculosis, and COVID-19 Testing in Nigeria.
    J Infect Dis. 2025;232.
    >> Share

  42. SATISH BA, Sundar S, Rajmani RS, Balaji KN, et al
    Activin A mediated KAT8 expression induces ferroptosis during Mycobacterium tuberculosis infection.
    J Infect Dis. 2025 Sep 22:jiaf482. doi: 10.1093.
    >> Share

  43. PAN C, Xu H, Huang M, He J, et al
    Mycobacterium tuberculosis PE_PGRS62 protein inhibits type I IFN responses to promote HIV-2 replication by directly interacting with IRF3.
    J Infect Dis. 2025 Sep 17:jiaf484. doi: 10.1093.
    >> Share

  44. RAO PS, Prakash Babu S, Ezhumalai K, Knudsen S, et al
    Rifampin Exposure in Pregnant and Non-Pregnant Women with Tuberculosis in India.
    J Infect Dis. 2025 Sep 10:jiaf467. doi: 10.1093.
    >> Share

    August 2025
  45. SARTI E, Dolle C, Wolfensberger R, Kusejko K, et al
    c-Myc inhibits macrophage antimycobacterial response in Mycobacterium tuberculosis infection.
    J Infect Dis. 2025 Aug 30:jiaf456. doi: 10.1093.
    >> Share

  46. BUI VL, Ragonnet R, Hughes AE, Shipman DS, et al
    Impact of Case Detection and Covid-19-Related Disruptions on Tuberculosis In Vietnam: A Modelling Analysis.
    J Infect Dis. 2025 Aug 7:jiaf406. doi: 10.1093.
    >> Share

  47. SOLANS BP, Miyakawa R, Shin M, Hesseling AC, et al
    Deriving Dosages for Levofloxacin Tuberculosis Preventive Treatment for Young People Exposed to Rifampicin-Resistant Tuberculosis.
    J Infect Dis. 2025 Aug 6:jiaf401. doi: 10.1093.
    >> Share

  48. DONOHUE S, Leisching G, Keane J
    The emerging role of immunothrombosis in the control and pathogenesis of Mycobacterium tuberculosis.
    J Infect Dis. 2025 Aug 5:jiaf415. doi: 10.1093.
    >> Share

  49. HUYNH J, Pretorius PM, Jan W, Kachramanoglou C, et al
    Brain imaging and whole blood targeted transcriptomic analyses to characterise cerebral infarctions in children with tuberculous meningitis.
    J Infect Dis. 2025 Aug 2:jiaf399. doi: 10.1093.
    >> Share

    July 2025
  50. BOUCAU J, Ruelas Castillo J, Naidoo T, Liu Y, et al
    Inflammatory macrophages associate with tissue injury and fibrosis in a mouse model of tuberculosis.
    J Infect Dis. 2025 Jul 8:jiaf361. doi: 10.1093.
    >> Share

  51. PEARSON RA, Krish KN, Whatney WE, Jaoko W, et al
    Single-cell transcriptomics reveals depletion and dysregulation of Mycobacterium tuberculosis-specific Th1 and Th17 cells early after acquisition of HIV.
    J Infect Dis. 2025 Jul 3:jiaf354. doi: 10.1093.
    >> Share

    June 2025
  52. KRAEF C, Omland LH, Porskrog A, Larsen CS, et al
    Risk of cancer after tuberculosis disease among people with HIV in Denmark: a nationwide population-based cohort study.
    J Infect Dis. 2025 Jun 26:jiaf341. doi: 10.1093.
    >> Share

  53. CHEN J, Zhao L, Zhou X, Mo Y, et al
    Safety and Diagnostic Performance of Recombinant Fusion Protein ESAT6-CPF10 Skin Test in A Large Population: A Phase IV Clinical Trial.
    J Infect Dis. 2025 Jun 25:jiaf332. doi: 10.1093.
    >> Share

  54. RYCKMAN TS, Hopkins L, Tang L, Biche P, et al
    Molecular epidemiology of Mycobacterium tuberculosis across three distinct geographic sites in South Africa.
    J Infect Dis. 2025 Jun 17:jiaf326. doi: 10.1093.
    >> Share

  55. HARIKUMAR PARVATHY G, Hertz D, Bhandiwad D, Eggers L, et al
    Sex Differences in Vaccine-Induced Immunity and Protection Against Mycobacterium tuberculosis.
    J Infect Dis. 2025 Jun 17:jiaf277. doi: 10.1093.
    >> Share

  56. NTSHIQA T, Nagudi J, Hamada Y, Copas A, et al
    Risk factors associated with TB infection among household contacts of microbiologically confirmed pulmonary TB patients in three high TB burden countries.
    J Infect Dis. 2025 Jun 17:jiaf320. doi: 10.1093.
    >> Share

  57. LEE BY, Clemens DL, Maslesa-Galic S, Nava S, et al
    Adding Intranasal to Oral Administration of an Ultra-rapid Near Universal Drug Regimen Accelerates Relapse-free Cure of Tuberculosis in Mice.
    J Infect Dis. 2025 Jun 11:jiaf315. doi: 10.1093.
    >> Share

  58. BUSTION AE, Ernest JP, Kaya F, Silva C, et al
    The kinetics of bedaquiline diffusion in tuberculous cavities open a window for emergence of resistance.
    J Infect Dis. 2025 Jun 4:jiaf303. doi: 10.1093.
    >> Share

  59. KLEYNHANS L, Maasdorp E, Snyders CI, Seddon JA, et al
    Impact of puberty on immune responses to Mycobacterium tuberculosis in South African adolescents.
    J Infect Dis. 2025 Jun 2:jiaf293. doi: 10.1093.
    >> Share

  60. NGARA B, Flori L, van Wijk RC, Ernest JP, et al
    Translational Modeling of BTZ-043 to Predict Phase 2A Efficacy and Evaluate Drug-Drug Interactions With Bedaquiline, Pretomanid, and Linezolid in Murine Models.
    J Infect Dis. 2025;231:e901-e911.
    >> Share

    May 2025
  61. MORO RN, Johnson JL, Martinson N, Muzanyi G, et al
    Differences in Neutrophil Counts Between African and non-African Countries in two International Clinical Trials.
    J Infect Dis. 2025 May 31:jiaf291. doi: 10.1093.
    >> Share

  62. VEEKEN LD, Schwalb A, Horton KC, Koesoemadinata RC, et al
    Mind the clinic-community gap: how concerned should we be about false positive test results in mass tuberculosis screening?
    J Infect Dis. 2025 May 23:jiaf268. doi: 10.1093.
    >> Share

  63. COLLINS JM, Bobosha K, Narayanan N, Gandhi NR, et al
    A plasma metabolic signature to diagnose pulmonary tuberculosis and monitor treatment response.
    J Infect Dis. 2025 May 8:jiaf240. doi: 10.1093.
    >> Share

    April 2025
  64. ABDELGAWAD N, Wasserman S, Gausi K, Davis A, et al
    Population Pharmacokinetics of Rifampicin in Plasma and Cerebrospinal Fluid in Adults With Tuberculosis Meningitis.
    J Infect Dis. 2025 Apr 29:jiaf178. doi: 10.1093.
    >> Share

  65. FERNANDEZ MC, Peterson GJ, Le C, Skerrett SJ, et al
    Interferon Gamma Stimulation Fails to Restrict Mycobacterium tuberculosis Growth in Human Monocyte-derived and Alveolar Macrophages.
    J Infect Dis. 2025 Apr 26:jiaf220. doi: 10.1093.
    >> Share

  66. MACKAY EA, Platt G, Peloquin CA, Brooks MB, et al
    Impact of pharmacogenetics on pharmacokinetics of first-line anti-tuberculosis drugs in the HIRIF trial.
    J Infect Dis. 2025 Apr 17:jiaf195. doi: 10.1093.
    >> Share

  67. LOURENS R, Singh G, Arendse T, Thwaites G, et al
    Tuberculous meningitis across the lifespan.
    J Infect Dis. 2025 Apr 8:jiaf181. doi: 10.1093.
    >> Share

    March 2025
  68. PALADINO ME, Riva MA
    Comment On: Respiratory Isolation for Tuberculosis: A Historical Perspective.
    J Infect Dis. 2025 Mar 26:jiaf161. doi: 10.1093.
    >> Share

  69. THEODOROU DJ, Theodorou SJ
    Respiratory isolation of patients with tuberculosis: Is the way forward paved?
    J Infect Dis. 2025 Mar 17:jiaf143. doi: 10.1093.
    >> Share

  70. FOLKESSON E, Froberg G, Sundling C, Schon T, et al
    Improved detection of extrapulmonary and paucibacillary pulmonary tuberculosis by Xpert MTB Host Response in a TB low endemic, high resource setting.
    J Infect Dis. 2025 Mar 6:jiaf110. doi: 10.1093.
    >> Share

    February 2025
  71. FU Y, Yang X, Ling Q, Huang Y, et al
    USP25 Promotes the Antimycobacterial Response of Macrophages Through Stabilizing B-Raf and C-Raf.
    J Infect Dis. 2025;231:366-377.
    >> Share

  72. NAN Y, Wang Y, Dong Y, Liu Y, et al
    Impact of Hypoxia-Inducible Factor-1alpha on Host Immune Metabolism and Tissue Damage During Mycobacterium bovis Infection.
    J Infect Dis. 2025;231:355-365.
    >> Share


  73. Correction to: Predictive Markers of Incident Tuberculosis in Close Contacts in Brazil and India.
    J Infect Dis. 2025 Feb 17:jiaf078. doi: 10.1093.
    >> Share

  74. CHOW FC, Kafeero P, Muhumuza P, Nakimbugwe M, et al
    Safety and Tolerability of a Short Course of Linezolid for the Treatment of Predominantly Moderate to Severe Tuberculous Meningitis in Adults with HIV.
    J Infect Dis. 2025 Feb 17:jiaf089. doi: 10.1093.
    >> Share

  75. DEKKERS BGJ, Kerstjens HAM, Breisnes HW, Leeming DJ, et al
    Azithromycin as host-directed therapy for pulmonary tuberculosis - a randomized pilot trial.
    J Infect Dis. 2025 Feb 11:jiaf069. doi: 10.1093.
    >> Share

  76. HUGHES JA, Solans BP, Garcia-Prats AJ, Draper HR, et al
    Pharmacokinetics and safety of clofazimine in children with rifampicin-resistant tuberculosis.
    J Infect Dis. 2025 Feb 11:jiaf057. doi: 10.1093.
    >> Share

  77. KOLLMANN TR, Amenyogbe N, Schaltz-Buchholzer F, Baek O, et al
    Is systemic dissemination of BCG following neonatal vaccination required for protection against M. tuberculosis?
    J Infect Dis. 2025 Feb 6:jiaf051. doi: 10.1093.
    >> Share

  78. KATES OS, Shah M
    Integrating Ethics in Public Health Guideline Development: Case Study of Guidelines on Respiratory Isolation for Persons With Tuberculosis in Community Settings.
    J Infect Dis. 2025;231:23-30.
    >> Share

  79. BONOMO EJ, Shah M
    Rights-Based Legal Considerations for Tuberculosis Isolation Practices in Community Settings in the Postpandemic Era.
    J Infect Dis. 2025;231:31-36.
    >> Share

    January 2025
  80. STOLTZ A, Nathavitharana RR, de Kock E, Ueckermann V, et al
    Estimating the Early Transmission Inhibition of new treatment regimens for drug-resistant tuberculosis.
    J Infect Dis. 2025 Jan 9:jiaf005. doi: 10.1093.
    >> Share

  81. KOIRALA A, Smith K, Britton PN, Howard-Jones AR, et al
    Protracted Tuberculosis Outbreak in a Pasifika Diaspora in Western Sydney, Australia: The Importance of Community Engagement.
    J Infect Dis. 2025 Jan 9:jiae619. doi: 10.1093.
    >> Share

  82. NOGUEIRA BMF, Rangel F, Andrade AMS, Daniel EA, et al
    Predictive Markers of Incident Tuberculosis in Close Contacts in Brazil and India.
    J Infect Dis. 2025 Jan 7:jiae642. doi: 10.1093.
    >> Share

    December 2024
  83. DAY CL, Njuguna IN, Cranmer LM, Whatney WE, et al
    Patterns and cofactors of polyfunctional mycobacteria-specific T cell response restoration following 6-month antiretroviral treatment in children living with HIV.
    J Infect Dis. 2024 Dec 18:jiae630. doi: 10.1093.
    >> Share

  84. MENDELSOHN SC, Andrade BB, Mbandi SK, Andrade AMS, et al
    Transcriptomic Signatures of Progression to Tuberculosis Disease Among Close Contacts in Brazil.
    J Infect Dis. 2024;230:e1355-e1365.
    >> Share

  85. SEARS CL, Shah M
    The Evolution of Tuberculosis Community Transmission Science and its Ethical and Legal Constructs.
    J Infect Dis. 2024 Dec 11:jiae612. doi: 10.1093.
    >> Share

    November 2024
  86. ZHAI PY, Zang X, Jiang T, Feng J, et al
    Health and Economic Impacts of Introducing Vaccae and Enhanced Drug-Resistant Tuberculosis Management Strategies in China.
    J Infect Dis. 2024 Nov 22:jiae590. doi: 10.1093.
    >> Share

  87. FERNANDES AI, Pinto AJ, Silverio D, Zedler U, et al
    Genetically diverse Mycobacterium tuberculosis isolates manipulate inflammasome activation and IL-1beta secretion independently of macrophage metabolic rewiring.
    J Infect Dis. 2024 Nov 21:jiae583. doi: 10.1093.
    >> Share

  88. RUELAS CASTILLO J, Guerrini V, Quijada D, Karanika S, et al
    Pharmacological inhibition of macrophage triglyceride biosynthesis pathways does not improve Mycobacterium tuberculosis control in infected mice.
    J Infect Dis. 2024 Nov 19:jiae577. doi: 10.1093.
    >> Share

  89. HUANG X, Wu J, Xu J, Wang H, et al
    Mycobacterium tuberculosis Antigen Rv1471 Induces Innate Immune Memory and Adaptive Immunity against Infection.
    J Infect Dis. 2024 Nov 14:jiae572. doi: 10.1093.
    >> Share

    October 2024
  90. THOMPSON RR, Kim S, Pelissari DM, Harada LO, et al
    High mortality rates among individuals misdiagnosed with tuberculosis: a matched retrospective cohort study of individuals diagnosed with tuberculosis in Brazil.
    J Infect Dis. 2024 Oct 28:jiae531. doi: 10.1093.
    >> Share

  91. BI J, Guo Q, Gong Y, Chen X, et al
    Troglitazone reduces intracellular Mycobacterium tuberculosis survival via macrophage autophagy through LKB1-AMPKalpha signaling.
    J Infect Dis. 2024 Oct 25:jiae523. doi: 10.1093.
    >> Share

  92. RAJAGOPALAN S, Rourke AK, Asare E, Kohlerschmidt DJ, et al
    Engineered Mycobacteriophage TM4::GeNL Rapidly Determines Bedaquiline, Pretomanid, Linezolid, Rifampicin, and Clofazimine Sensitivity in Mycobacterium tuberculosis Clinical Isolates.
    J Infect Dis. 2024 Oct 16:jiae438. doi: 10.1093.
    >> Share

  93. SCHALTZ-BUCHHOLZER F, Nielsen S, Sorensen MK, Gomes GM, et al
    Maternal Bacille Calmette-Guerin Scars and Mortality Risk for Male and Female Newborns: Observational Study From Guinea-Bissau.
    J Infect Dis. 2024;230:995-1003.
    >> Share

  94. RIOPEL ND, Long R, Heffernan C, Tyrrell GJ, et al
    Characterization of Mycobacterium orygis, Mycobacterium bovis, and Mycobacterium caprae Infections in Humans in Western Canada.
    J Infect Dis. 2024;230:e789-e797.
    >> Share

  95. NATHAVITHARANA RR, Pearl A, Biewer A, Tzelios C, et al
    Assessing infectiousness and the impact of effective treatment to guide isolation recommendations for people with pulmonary tuberculosis.
    J Infect Dis. 2024 Oct 7:jiae482. doi: 10.1093.
    >> Share

  96. KARAKOUSIS PC, Mooney G
    Respiratory Isolation for Tuberculosis: A Historical Perspective.
    J Infect Dis. 2024 Oct 7:jiae477. doi: 10.1093.
    >> Share

    September 2024
  97. WALKER NF, Schutz C, Ward A, Barr D, et al
    Elevated Plasma Matrix Metalloproteinases Are Associated With Mycobacterium tuberculosis Bloodstream Infection and Mortality in Human Immunodeficiency Virus-Associated Tuberculosis.
    J Infect Dis. 2024 Sep 2:jiae296. doi: 10.1093.
    >> Share

    August 2024
  98. HORTON KC, McCaffrey T, Richards AS, Schwalb A, et al
    Estimating the impact of tuberculosis pathways on transmission - what is the gap left by passive case-finding?
    J Infect Dis. 2024 Aug 6:jiae390. doi: 10.1093.
    >> Share

    July 2024
  99. CLARK RA, Sumner T, Weerasuriya CK, Bakker R, et al
    Estimating the Potential Public Health Value of BCG Revaccination.
    J Infect Dis. 2024;230:e139-e143.
    >> Share

  100. GILS T, Hella J, Jacobs BKM, Sossen B, et al
    A prospective evaluation of the diagnostic accuracy of the point-of-care VISITECT CD4 Advanced Disease test in seven countries.
    J Infect Dis. 2024 Jul 24:jiae374. doi: 10.1093.
    >> Share

  101. RAJAMANICKAM A, Ann Daniel E, Dasan B, Thiruvengadam K, et al
    Plasma Immune Biomarkers Predictive of Progression to Active Tuberculosis in Household Contacts of TB Patients.
    J Infect Dis. 2024 Jul 19:jiae365. doi: 10.1093.
    >> Share

  102. KARLSSON L, Ohrnberg I, Sayyab S, Martinez-Enguita D, et al
    A DNA Methylation Signature from Buccal Swabs to Identify Tuberculosis Infection.
    J Infect Dis. 2024 Jul 4:jiae333. doi: 10.1093.
    >> Share

    June 2024
  103. MUDDE SE, Ammerman NC, Ten Kate MT, Fotouhi N, et al
    Relative contributions of the novel diarylquinoline TBAJ-876 and its active metabolite to the bactericidal activity in a murine model of tuberculosis.
    J Infect Dis. 2024 Jun 28:jiae332. doi: 10.1093.
    >> Share

  104. SINHA P, Guerrant RL
    The Costly Vicious Cycle of Infections and Malnutrition.
    J Infect Dis. 2024;229:1611-1613.
    >> Share

    May 2024
  105. ARRIAGA MB, Amorim G, Figueiredo MC, Staats C, et al
    Effect of Smoking on Longitudinal Interferon-Upsilon Release Assay Results among Close Contacts of People with Pulmonary Tuberculosis.
    J Infect Dis. 2024 May 31:jiae285. doi: 10.1093.
    >> Share

  106. DIXIT A, Ektefaie Y, Kagal A, Freschi L, et al
    Drug resistance and epidemiological success of modern Mycobacterium tuberculosis lineages in western India.
    J Infect Dis. 2024 May 31:jiae240. doi: 10.1093.
    >> Share

  107. MEIWES L, Kontsevaya I, Chesov D, Kulcitkaia S, et al
    Whispers in the wind: Face mask sampling for Mycobacterium tuberculosis detection in children with pulmonary tuberculosis.
    J Infect Dis. 2024 May 27:jiae282. doi: 10.1093.
    >> Share

  108. SPRINGER YP, Tompkins ML, Newell K, Jones M, et al
    Characterizing the etiology of recurrent tuberculosis using whole genome sequencing-Alaska, USA, 2008-2020.
    J Infect Dis. 2024 May 24:jiae275. doi: 10.1093.
    >> Share

  109. ESPINOSA-PEREIRO J, Alagna R, Saluzzo F, Gonzalez-Moreno J, et al
    A Systematic Review of Potential Biomarkers for Bacterial Burden and Treatment Efficacy Assessment in Tuberculosis Platform-Based Clinical Trials.
    J Infect Dis. 2024;229:1584-1595.
    >> Share

  110. TAGAMI Y, Horita N, Kaneko M, Muraoka S, et al
    Whole-Genome Sequencing Predicting Phenotypic Antitubercular Drug Resistance: Meta-analysis.
    J Infect Dis. 2024;229:1481-1492.
    >> Share

  111. PETRILLO S, Di Prinzio RR, Quatrana A, Santoro A, et al
    Redox biomarkers in asymptomatic latent human tuberculosis: a comparison with active disease.
    J Infect Dis. 2024 May 9:jiae254. doi: 10.1093.
    >> Share

  112. BALASINGAM S, Dheda K, Fortune S, Gordon SB, et al
    Review of the current TB human infection studies for use in accelerating TB vaccine development: A meeting report.
    J Infect Dis. 2024 May 6:jiae238. doi: 10.1093.
    >> Share

    April 2024
  113. MORO RN, Mehaffy C, De P, Phillips E, et al
    Assessment for Antibodies to Rifapentine and Isoniazid in Persons Developing Flu-like Reactions During Treatment of Latent Tuberculosis Infection.
    J Infect Dis. 2024 Apr 19:jiae180. doi: 10.1093.
    >> Share

  114. CROSS GB, O' Doherty J, Chang CC, Kelleher AD, et al
    Does PET-CT Have a Role in the Evaluation of Tuberculosis Treatment in Phase 2 Clinical Trials?
    J Infect Dis. 2024;229:1229-1238.
    >> Share

  115. TAIT D, Diacon A, Borges AH, van Brakel E, et al
    Safety and immunogenicity of the H56:IC31 tuberculosis vaccine candidate in adults successfully treated for drug-susceptible pulmonary TB: a phase 1 randomized trial.
    J Infect Dis. 2024 Apr 1:jiae170. doi: 10.1093.
    >> Share

    March 2024
  116. PATON NI, Gurumurthy M, Lu Q, Leek F, et al
    Adjunctive pascolizumab in rifampicin-susceptible pulmonary tuberculosis: proof-of-concept, partially-randomised, double-blind, placebo-controlled, dose-escalation trial.
    J Infect Dis. 2024 Mar 25:jiae104. doi: 10.1093.
    >> Share

  117. OLSSON O, Sokilde R, Tesfaye F, Karlson S, et al
    Tuberculosis disease is associated with elevated plasma ribonuclease activity in antiretroviral treatment-naive people with HIV.
    J Infect Dis. 2024 Mar 25:jiae143. doi: 10.1093.
    >> Share

    February 2024
  118. XIAO G, Huang W, Zhong Y, Ou M, et al
    Uncovering the Bronchoalveolar Single-Cell Landscape of Patients With Pulmonary Tuberculosis With Human Immunodeficiency Virus Type 1 Coinfection.
    J Infect Dis. 2024 Feb 27:jiae042. doi: 10.1093.
    >> Share

  119. OH IS, Kim JH, Huh K, Jang SH, et al
    Impact of National Public-Private Mix and Medical Expense Support Program for Control Tuberculosis in South Korea: An Interrupted Time Series Analysis.
    J Infect Dis. 2024 Feb 14:jiae059. doi: 10.1093.
    >> Share

  120. CHAUHAN KS, Dunlap MD, Akter S, Gupta A, et al
    NF-kappaB signaling deficiency in CD11c-expressing phagocytes mediates early inflammatory responses and enhances Mycobacterium tuberculosis control.
    J Infect Dis. 2024 Feb 7:jiae060. doi: 10.1093.
    >> Share

    January 2024
  121. ZHENG Q, Li Z, Zhou Y, Li Y, et al
    Heparin-binding hemagglutinin of Mycobacterium tuberculosis inhibits autophagy via TLR4 and drives M2 polarization in macrophages.
    J Infect Dis. 2024 Jan 24:jiae030. doi: 10.1093.
    >> Share

  122. PEI X, Zhong T, Yang C, Sun L, et al
    Cost-Effectiveness of Community-Based Active Case Finding Strategy for Tuberculosis: Evidence from Shenzhen, China.
    J Infect Dis. 2024 Jan 23:jiae024. doi: 10.1093.
    >> Share

  123. RIDOLFI F, Amorim G, Peetluk LS, Haas DW, et al
    Prediction models for adverse drug reactions during tuberculosis treatment in Brazil.
    J Infect Dis. 2024 Jan 23:jiae025. doi: 10.1093.
    >> Share

  124. HUYNH J, Le NHT, Nguyen BHL, Hoang HT, et al
    The ability of a 3-gene host signature in blood to distinguish tuberculous meningitis from other brain infections.
    J Infect Dis. 2024 Jan 3:jiad606. doi: 10.1093.
    >> Share

    December 2023
  125. ZAINABADI K, Vilbrun SC, Mathurin LD, Walsh KF, et al
    A bedaquiline, pyrazinamide, levofloxacin, linezolid, clofazimine second line regimen for tuberculosis displays similar early bactericidal activity as the standard rifampin based first line regimen.
    J Infect Dis. 2023 Dec 7:jiad564. doi: 10.1093.
    >> Share

    November 2023
  126. BLAZEVIC A, Edwards RL, Xia M, Eickhoff CS, et al
    Phase 1 Open-Label Dose Escalation Trial for the Development of a Human Bacillus Calmette-Guerin Challenge Model for Assessment of Tuberculosis Immunity In Vivo.
    J Infect Dis. 2023 Nov 29:jiad441. doi: 10.1093.
    >> Share

  127. YUEN CM, Huang CC, Millones AK, Calderon RI, et al
    Utility of Mycobacterium tuberculosis genome sequencing snapshots to assess transmission dynamics over time.
    J Infect Dis. 2023 Nov 23:jiad515. doi: 10.1093.
    >> Share

    October 2023
  128. SINGH B, Pahuja I, Yadav P, Shaji A, et al
    Adjunct therapy with all-trans-retinoic acid improves therapeutic efficacy through immunomodulation while treating tuberculosis with antibiotics in a murine model.
    J Infect Dis. 2023 Oct 21:jiad460. doi: 10.1093.
    >> Share

    September 2023
  129. ESCUDERO JN, Mecha J, Richardson BA, Maleche-Obimbo E, et al
    Impact of HIV and peripartum period on Mycobacterium tuberculosis infection detection.
    J Infect Dis. 2023 Sep 28:jiad416. doi: 10.1093.
    >> Share

  130. ABDELGAWAD N, Wasserman S, Abdelwahab MT, Davis A, et al
    Linezolid population pharmacokinetic model in plasma and cerebrospinal fluid among patients with tuberculosis meningitis.
    J Infect Dis. 2023 Sep 22:jiad413. doi: 10.1093.
    >> Share

  131. NORE KG, Louet C, Bugge M, Gidon A, et al
    The Cyclooxygenase 2 inhibitor etoricoxib as adjunctive therapy in tuberculosis impairs macrophage control of mycobacterial growth.
    J Infect Dis. 2023 Sep 18:jiad390. doi: 10.1093.
    >> Share

  132. RASI V, Phelps KR, Paulson KR, Eickhoff CS, et al
    Homodimeric Granzyme A opsonizes Mycobacterium tuberculosis and inhibits its intracellular growth in human monocytes via TLR4 and CD14.
    J Infect Dis. 2023 Sep 6:jiad378. doi: 10.1093.
    >> Share

    August 2023
  133. HILL PC, Cobelens F, Martinez L, Behr MA, et al
    An aspiration to radically shorten phase 3 TB vaccine trials.
    J Infect Dis. 2023 Aug 22:jiad356. doi: 10.1093.
    >> Share

  134. MCSHANE H
    Improving TB vaccine trial efficiency: A tough nut to crack.
    J Infect Dis. 2023 Aug 21:jiad360. doi: 10.1093.
    >> Share

    June 2023
  135. MAENETJE P, Baik Y, Schramm DB, Vangu MDW, et al
    Circulating biomarkers, FeNO, and lung function in patients with HIV and tuberculosis.
    J Infect Dis. 2023 Jun 30:jiad232. doi: 10.1093.
    >> Share

  136. SINGH DK, Bhaskar A, Pahuja I, Shaji A, et al
    Co-treatment with Clofazimine and Rapamycin eliminates drug-resistant tuberculosis by inducing polyfunctional central memory T cell responses.
    J Infect Dis. 2023 Jun 8:jiad214. doi: 10.1093.
    >> Share

    May 2023
  137. CHEN S, Li C, Qin Z, Song L, et al
    Serum metabolomic profiles for distinguishing lung cancer from pulmonary tuberculosis: identification of rapid and noninvasive biomarker.
    J Infect Dis. 2023 May 29:jiad175. doi: 10.1093.
    >> Share

  138. RAMALINGAM S, Kumar A, Krug S, Mohan H, et al
    CRISPR correction of GBA mutation in hiPSCs restores normal function to Gaucher macrophages and increases their susceptibility to Mycobacterium tuberculosis.
    J Infect Dis. 2023 May 9:jiad141. doi: 10.1093.
    >> Share

  139. BORBORA SM, Satish BA, Sundar S, B M, et al
    Mycobacterium tuberculosis elevates SLIT2 expression within the host and contributes to oxidative stress responses during infection.
    J Infect Dis. 2023 May 9:jiad126. doi: 10.1093.
    >> Share

    April 2023
  140. VAN DER HEIJDEN YF, Maruri F, Blackman A, Morrison R, et al
    Mycobacterium tuberculosis gene expression associated with fluoroquinolone resistance and efflux pump inhibition.
    J Infect Dis. 2023 Apr 20:jiad112. doi: 10.1093.
    >> Share

  141. ALEMNJI G, Mosha F, Maggiore P, Alexander H, et al
    Building Integrated Testing Programs for Infectious Diseases.
    J Infect Dis. 2023 Apr 12:jiad103. doi: 10.1093.
    >> Share

  142. ROCCO JM, Laidlaw E, Galindo F, Anderson M, et al
    Mycobacterial Immune Reconstitution Inflammatory Syndrome in HIV is Associated With Protein-Altering Variants in Hemophagocytic Lymphohistiocytosis-Related Genes.
    J Infect Dis. 2023 Apr 11:jiad059. doi: 10.1093.
    >> Share

    February 2023
  143. SABO MC, Thuong NTT, Chang X, Ardiansyah E, et al
    MUC5AC genetic variation is associated with tuberculous meningitis CSF cytokine responses and mortality.
    J Infect Dis. 2023 Feb 24:jiad050. doi: 10.1093.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016